Browse All

Current Filters

CLEAR FILTER x

TITLE

Phase 3 Myasthenia Gravis Inebilizumab Trial (MINT): Minimal Symptom Expression Achievement with Inebilizumab

Author:Richard Nowak  Michael Benatar  Emma Ciafaloni  M. Isabel Leite  Kimiaki Utsugisawa  John Vissing  Sarah Bray  Blanca Canales  Kristina Patterson  Catherine Najem  Sue Cheng  James Howard  

Topic:Autoimmune Neurology  

Program Number:P1.055  

Author Institution:Yale University, New Haven, CT, USA, New Haven, CT  University of Miami Miller School of Medicine, Miami, FL, USA, Miami, FL  University of Rochester, Rochester, NY, USA, Rochester, NYHanamaki General Hospital, Hanamaki, Japan, Hanamaki, Japan  University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark  Amgen Ltd., Cambridge, United Kingdom  Amgen Inc., Thousand Oaks, CA, USA, Humble, TXAmgen Inc., Thousand Oaks, CA, USA, Horsham, PAUniversity of North Carolina, Chapel Hill, NC, USA, Chapel Hill, NC